Skip to content

Study on the Effect of Changes in DPP IV Expression/Activity Change on AMPK/SIRT1/NRF2/HO1 Signaling Pathway Expression in Papillary Thyroid Carcinoma Patients with Type 2 Diabetic

Study on the Effect of Changes in DPP IV Expression/Activity Change on AMPK/SIRT1/NRF2/HO1 Signaling Pathway Expression in Papillary Thyroid Carcinoma Patients with Type 2 Diabetic

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074756
Enrollment
Unknown
Registered
2023-08-15
Start date
2023-08-20
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paillary thyroid carcinoma

Interventions

Group A: Tumor tissue of T2DM patients with PTC:None
Group B: normal tissue adjacent to tumor in T2DM patients with PTC:None
Group C: Tumor tissue of PTC patients with completely normal glucose metabolism:None
Group D: normal tissues adjacent to tumors of PTC patients with completely normal glucose metabolism:None
Group E: Thyroid lesions in T2DM patients with benign thyroid disease:None
Group F: normal tissue adjacent to thyroid lesions in T2DM patients with benign thyroid diseases:None
Group G: Thyroid lesions in benign thyroid disease patients with completely normal glucose metabolism:None
Group H: Normal tissues adjacent to thyroid lesions in benign thyroid disease patients with completely normal glucose metabolism:None

Sponsors

Dalian Municipal Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Adults aged 18 years or older; ? The diagnosis of type 2 diabetes with papillary thyroid carcinoma or benign thyroid tumor should be made after the diagnosis of type 2 diabetes and the history of diabetes =1 year; ?Paillary thyroid carcinoma tissue and thyroid benign tumor tissue need to be confirmed by postoperative pathology. (4) Para-tumor tissue should be pathologically confirmed as normal thyroid tissue; ?Tumor tissue and adjacent normal tissue samples were collected without receiving any form of thyroid surgery and chemoradiotherapy; ? Complete clinical and pathological data.

Exclusion criteria

Exclusion criteria: ? Type 1 diabetes mellitus, gestational diabetes mellitus and other special types of diabetes mellitus; ? Serious cardiovascular and cerebrovascular diseases or serious kidney, liver, lung diseases; ? Patients with endocrine malignant tumors and malignant tumors of other systems except thyroid cancer.

Design outcomes

Primary

MeasureTime frame
DPP IV ;fasting blood gulcose;FT3;FT4;TSH;height;weight;

Secondary

MeasureTime frame
AMPK;SIRT1;NRF2 ;HO1;TGAb;TPOAb;thyroid ultrasound;

Countries

China

Contacts

Public ContactXinyu Li

Dalian Municipal Central Hospital

Xuhanliu281277@hotmail.com+86 135 5596 3206

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026